Modality
Gene Therapy
MOA
PARPi
Target
CGRP
Pathway
RAS/MAPK
WM
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
May 2023
→ Apr 2026
Phase 1Current
NCT06289144
1,351 pts·WM
2023-05→2026-04·Completed
1,351 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-022d awayInterim· WM
2026-05-041mo awayConference· WM
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Complet…
Catalysts
Interim
2026-04-02 · 2d away
WM
Conference
2026-05-04 · 1mo away
WM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06289144 | Phase 1 | WM | Completed | 1351 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |